The technical performance of a newly developed assay for CA M43, a serum marker for colorectal cancer, was evaluated and its preliminary clinical potential assessed. The heterologous double-determinant enzyme immunoassay for the detection of the tumor-associated mucin CA M43 utilizes two monoclonal antibodies (CT 43 and CT 66) selected for their binding capacity to two distinct epitopes present on mucins in the sera of patients with colorectal cancer. CT 66 recognizes both Lewisa and sialylated Lewisa antigen; CT 43 is directed toward a mucin epitope of an as-yet uncharacterized structure. Precision experiments revealed interassay CVs of 11.8%, 5.9%, and 4.9% at 9.3, 11.9, and 78.9 units/mL, respectively; intraassay precision was 2.0% at 95.1 units/mL. The upper normal value was set at 7.5 units/mL, which included 99% of the values found in healthy controls. In colorectal cancer patients, CA M43 showed a positivity rate equivalent to that of carcinoembryonic antigen (CEA) and superior to that of CA 19.9, with only one CA 19.9-positive serum being negative for CA M4.3. Interestingly, CA M43 appeared to be complementary to CEA, with CA M43 and CEA together reaching 87% positivityin metastatic disease. 
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tumor markers
In recent years, efforts have been made to develop new marker systems for various cancer types. Of the many antibodies generated for this purpose, monoclonal antibodies that recognize specificepitopes on large glycoprothins of mucin origin seem to be the most promising and have been incorporated in various test systems (1) (2) (3) (4) (5) .
The newly developed CA M43 enzyme immunoassay is one of a new line of second-generation anti-mucin serum tumor marker tests, which started with the CA M26 and CA M29 assays (6) (7) (8) (9) 
Follow-up.
The determination of CA M43 in the follow-up sera of nine patients with colorectal carcinoma provided additional information in only some cases. CEA best reflected the course of disease in four cases, with the other two markers giving less information (Figure 1) .
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Colitis ulcerosa (n=17)
CA M43 CA 19.9 CEA The CA 19.9 assay makes use of a specific monoclonal antibody that detects only the sialylated Lewisa antigen, in a homologous assay. The CA M43 assay combines two monoclonal antibodies, specific for two distinct epitopes, in an unmunoassay with better specificity and better sensitivity (10). The tracer monoclonal antibody CT66 binds both to ja and sialylated The interassay reproducibility of CA M43 was satisfactory, both in the slightly increased borderline range and in the higher concentration range. Intraassay reproducibility was well within the usually accepted ranges for tests of this type. Test results did not differ significantly between apparently healthy male and female control subjects. The upper normal limit was set at 7.5 unitslmL, with 99% of all controls lying below this concentration. Applying this cutoff value, we found a positivity rate slightly better than that of CEA in pretreatment serum samples from colorectal cancer patients.
Our results suggest an application of CA M43 in the management of colorectal cancer patients in combination with CEA. The combination of CEA and CA M43 resulted in a higher positivity rate and better diagnostic accuracy than that for each marker individually, especially in the group of patients with metastatic disease.
The best overall performance in the follow-up of colorectal cancer patients (Figure 1) was provided by CEA, with CA M43 and (or) CA 19.9 giving parallel results to CEA in some cases. The role of CA M43 detection in the follow-up of colorectal cancer should be further defined in a prospective study involving a larger group of patients.
The combination of CA M43 with CEA merits further study in the diagnosis, treatment monitoring, and follow-up of patients with colorectal cancer.
